Servier buys PIXUVRI Non-Hodgkin lymphoma therapy from CTI BioPharma
Category: #health  By Saipriya Iyer  Date: 2019-10-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Servier buys PIXUVRI Non-Hodgkin lymphoma therapy from CTI BioPharma

A substantial rise in occurrence of cancer cases is being witnessed across the globe lately. Various global pharmaceutical firms are increasingly working towards discovering novel, innovative treatments that effectively address cancer growth to minimize the effect the disease has on people’s lives. These drug discovery efforts in the pharmaceutical sector are typically fueled through acquisitions and collaborations.

Servier, a global pharmaceutical firm headquartered in Neuilly-sur-Seine, France, reportedly announced the acquisition of PIXUVRI®, a non-Hodgkin B-cell lymphoma treatment, from Seattle based biopharmaceutical firm, CTI BioPharma.

PIXUVRI is a therapy for adult patients with multiple refractory or relapsed aggressive Non-Hodgkin B-cell lymphoma. CTI Biopharma and Servier signed an Asset Purchase Agreement, according to which the global rights for PIXUVRI have been transferred to Servier.

Servier commercialized PIXUVRI across the globe, in all nations where this drug was authorized for distribution under exclusive license from the American pharmaceutical firm.

Executive VP, Global Head of R&D of Servier, Claude Bertrand stated that the PIXUVRI acquisition is a crucial step towards the company’s long-term strategy of becoming an important player in oncology. In oncology, one of the prime focuses of the firm is hematology, and now the firm has two medicines which are globally marketed along with an innovative and strong pipeline of the drug candidates including CAR-T therapies.

Bertrand further added that as a part of the company strategy, Servier is committed at investing 50% of its R&D budget in the oncology field.

Non-Hodgkin lymphoma (NHL) is a type of blood cancer which affects lymphatic system, it could occur in various body parts from the lymph nodes present in the neck to the spleen or the liver, but it can also occur in other organs like the small bowel, stomach, brain, bones, skin or testicles.

Globally there are more than 500,000 new cases of Non-Hodgkin lymphoma per year. NHL is both the world’s 11th most commonly detected cancer as well as a common cause of deaths due to cancer.

VP, Global Head of Business Development & Licensing, Servier, Eric Falcand stated that the company has a strong commitment to offer effective solutions for patients with cancer. PIXUVRI lymphoma treatment is an effective cancer therapy, it has received standard marketing authorization earlier in June from the European Medicines Agency, and now to achieve long term goals of Servier, the company assures that patients will have easy access to PIXUVRI.

 

Source credit: https://www.businesswire.com/news/home/20190930005875/en/Servier-acquires-non-Hodgkin-B-cell-lymphoma-treatment-PIXUVRI%C2%AE



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...

Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
By Saipriya Iyer

Reliance Industries Ltd., an Indian conglomerate, has reportedly raised Rs.7,500 crore (Dollar 1.02 billion) by selling a stake in its retail unit to Silver Lake Partners, a private equity firm.

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
By Saipriya Iyer

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec G...